CPO and infection: Currently, in severe CPO-positive infections, high-dose strategies and synergies involving new combinations of old β-lactams with new β-lactamase inhibitors should be considered as they may contribute to therapeutic success, e.g., the synergy of ceftazidime/avibactam with aztreonam or meropenem/vaborbactam with aztreonam.